Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number o...

Descripción completa

Detalles Bibliográficos
Autores principales: Demirci, Ayşe, Bilir, Cemil, Gülbağcı, Burcu, Hacıbekiroğlu, İlhan, Bayoğlu, İbrahim V., Bilgetekin, İrem, Koca, Sinan, Çınkır, Havva Y., Akdeniz, Nadiye, Gül, Deniz, Varım, Ceyhun, Demirci, Umut, Öksüzoğlu, Berna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266820/
https://www.ncbi.nlm.nih.gov/pubmed/34239026
http://dx.doi.org/10.1038/s41598-021-93659-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266820/
https://www.ncbi.nlm.nih.gov/pubmed/34239026
http://dx.doi.org/10.1038/s41598-021-93659-x

Ejemplares similares